Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.45 |
| ▸ | GRM8 | O00222 | 1/20 | 0.45 |
| ▸ | GRM6 | O15303 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.45 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.45 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.45 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15634459 | 1.00 | GSR (0.45) | GSRGRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL826933 | 0.88 | GSR (0.48) | GSRGRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL231631 | 0.88 | GSR (0.48) | GSRGRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL5668298 | 0.88 | GSR (0.48) | GSRGRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL10238195 | 0.86 | GSR (0.52) | GSRGRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL21083190 | 0.85 | GSR (0.50) | GSRGRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL826645 | 0.85 | GSR (0.50) | GSRGRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL11940102 | 0.82 | SLC7A5 (0.30) | SLC7A5 | |
| SCHEMBL19417862 | 0.81 | GSR (0.46) | GSRGRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL10418773 | 0.80 | ENPEP (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-20230348547-A1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | AMBRX INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | AMBRX, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230226152-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | AMBRX, INC. | 2023-07-20 | — | — | US | disclosed |
| EP-3225248-B1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | AMBRX INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20080177027-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080125574-A1 | Blood plasma protein for use as carrier medical therapeutics | AMBRX, INC. (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080125574-A1 | Blood plasma protein for use as carrier medical therapeutics | AMBRX, INC. (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080107680-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080107680-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080102125-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080102125-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-7332571-B2 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332571-B2 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| WO-2006069220-A9 | MODIFIED HUMAN GROWTH HORMONE | AMBRX INC (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226152-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | IL2, IL2RA, TAP2 | GSR 3523/4885GRM8 4167/4885GRM6 4027/4885 |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | GSR 4873/4885GRM8 4218/4885GRM6 3333/4885 |
| US-20080125574-A1 | Blood plasma protein for use as carrier medical therapeutics | SERPINA6, FUCA2, F13B | GSR 4345/4885GRM8 2790/4885GRM6 2110/4885 |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | GSR 4178/4885GRM8 270/4885GRM6 412/4885 |
| US-20080102125-A1 | Modified Human Growth Hormone | GHRHR, GHITM, GHSR | GSR 3937/4885GRM8 945/4885GRM6 690/4885 |
| US-20230348547-A1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | CSF3R, GMFG, HDGF | GSR 2625/4885GRM8 1248/4885GRM6 1002/4885 |
| US-20080177027-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | DNPEP, DAO, PTMS | GSR 2484/4885GRM8 3440/4885GRM6 2446/4885 |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | CD63, CD74, CD99 | GSR 4870/4885GRM8 4259/4885GRM6 3393/4885 |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | RXFP1, RXFP2, RXFP3 | GSR 3276/4885GRM8 910/4885GRM6 724/4885 |
| US-20080107680-A1 | Modified Human Growth Hormone | GHRHR, GHITM, GHSR | GSR 3937/4885GRM8 945/4885GRM6 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.